Antibody Therapeutics Investment Landscape for Neurodegeneration

Migration, Crosslink

📖

Antibody Therapeutics Investment Landscape for Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-investment-antibody-therapeutics-ne

📖 Wiki Page

investment796 wordssynced 2026-04-02

Overview

flowchart TD investment_antibody_therapeuti["Antibody Therapeutics Investment Landscape for N"] style investment_antibody_therapeuti fill:#4fc3f7,stroke:#333,color:#000 investment_antibody__0["Market Landscape"] investment_antibody_therapeuti -->|"includes"| investment_antibody__0 style investment_antibody__0 fill:#81c784,stroke:#333,color:#000 investment_antibody__1["Key Players"] investment_antibody_therapeuti -->|"includes"| investment_antibody__1 style investment_antibody__1 fill:#ef5350,stroke:#333,color:#000 investment_antibody__2["Investment Themes"] investment_antibody_therapeuti -->|"includes"| investment_antibody__2 style investment_antibody__2 fill:#ffd54f,stroke:#333,color:#000 investment_antibody__3["Clinical Pipeline"] investment_antibody_therapeuti -->|"includes"| investment_antibody__3 style investment_antibody__3 fill:#ce93d8,stroke:#333,color:#000 investment_antibody__4["Anti-Amyloid Antibodies"] investment_antibody_therapeuti -->|"includes"| investment_antibody__4 style investment_antibody__4 fill:#4fc3f7,stroke:#333,color:#000 investment_antibody__5["Anti-Tau Antibodies"] investment_antibody_therapeuti -->|"includes"| investment_antibody__5 style investment_antibody__5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

This page tracks investment trends, pipeline developments, and commercial opportunities in antibody therapeutics for neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).

Market Landscape

Key Players

| Company | Focus Areas | Notable Programs | Market Cap (2026) |
|---------|-------------|------------------|-------------------|
| [Biogen](/companies/biogen) | AD, PD | [Lecanemab](/entities/lecanemab)[@van2023], Aducanumab | $25B |
| [Roche](/companies/roche) | AD | Gantenerumab[@ostrowitzki2022], Crenezumab | $280B |
| [Eli Lilly](/companies/eli-lilly) | AD | [Donanemab](/entities/donanemab)[@mintun2023], Solanezumab | $320B |
| [Johnson & Johnson](/companies/johnson-johnson) | AD, PD | [Tau](/proteins/tau) antibodies (Phase II) | $400B |
| [AbbVie](/companies/abbvie) | AD | ABBV-916 (anti-[Aβ](/proteins/amyloid-beta) protofibril) | $250B |
| [Prothelia](/companies/prothelia) | ALS, FTD | ALZ-101 (anti-tau) | $500M |

Investment Themes

Amyloid-targeting antibodies - Lecanemab, Donanemab showed clinical efficacy in clearing amyloid plaques

Tau-targeting antibodies - Anti-tau antibodies in various trial phases for AD and FTD

[Alpha-synuclein](/proteins/alpha-synuclein) antibodies - PD-focused immunotherapies targeting Lewy body formation

[TDP-43](/mechanisms/tdp-43-proteinopathy) antibodies - Emerging area for ALS and FTD

Bispecific antibodies - Next-generation constructs targeting multiple pathways

Fc engineering - Half-life extension and reduced ARIA risk

Clinical Pipeline

Anti-Amyloid Antibodies

| Drug | Company | Phase | Target | Indication | Status |
|------|---------|-------|--------|------------|--------|
| Lecanemab | Biogen/Eisai | Approved | Aβ protofibrils | Early AD | Commercial |
| Donanemab | Eli Lilly | Approved | N-terminal Aβ | Early AD | Commercial |
| Gantenerumab | Roche | Phase III | Amyloid plaques | Early AD | Failed |
| Crenezumab | Roche | Phase III | Oligomeric Aβ | Preclinical AD | Failed |
| Solanezumab | Eli Lilly | Phase III | Mid-domain Aβ | Preclinical AD | Failed |
| Donanemab | Eli Lilly | Phase III | N-terminal Aβ | Early AD | Approved |
| ALZ-801 | Alzheon | Phase III | Amyloid aggregation | Early AD | Ongoing |

Anti-Tau Antibodies

| Drug | Company | Phase | Target | Indication |
|------|---------|-------|--------|------------|
| Semorinemab | Roche/Genentech | Phase II | Tau | AD |
| Gosuranemab | Biogen | Phase II | Tau | AD |
| Tilavonemab | AbbVie | Phase II | Tau | AD |
| JNJ-63733657 | J&J | Phase I | Tau | AD |
| ABBV-8E12 | AbbVie | Phase II | Tau | FTD |

Anti-Alpha-Synuclein Antibodies

| Drug | Company | Phase | Target | Indication |
|------|---------|-------|--------|------------|
| Cinpanemab | Biogen | Phase II | α-syn | PD |
| Prasinezumab | Roche | Phase II | α-syn | PD |
| ABBV-951 | AbbVie | Phase I | α-syn | PD |

Bispecific Antibodies

| Drug | Company | Phase | Mechanism | Indication |
|------|---------|-------|-----------|------------|
| AC Immune/Roche | Bispecific | Phase I | Tau/Aβ | AD |
| Biogen/TCR | Bispecific | Phase I | Tau | AD |

Funding Trends

Investment by Indication (2024-2026)

AD: ████████████████████ $4.2B
PD: ████████████ $2.1B
ALS: ████████ $1.4B
FTD: ████ $620M
Other: ██ $380M

Recent Financing Rounds

2025 Q4: Prothelia $150M Series C for ALZ-101
2025 Q3: AC Immune $80M for bispecific pipeline
2025 Q2: AriBio $45M Series B for ARDC program
2025 Q1: Novo Nordisk $200M for neurodegeneration (via acquisitions)

Gap Analysis

Unmet Needs

Early intervention antibodies - Preventive antibodies for prodromal AD

Combination therapies - Antibody combinations targeting multiple pathways

[Blood-brain barrier](/entities/blood-brain-barrier) delivery - Enhanced CNS penetration

Biomarker-driven patient selection - Tau PET, CSF biomarkers

Real-world effectiveness - Long-term outcome data

Generic/biosimilar pathways - Post-patent strategies

Investment Opportunities

Anti-TDP-43 antibodies for ALS/FTD (minimal competition)

Anti-GER antibody for FTD (emerging target)

Antibody fragments (Fabs, scFvs) for improved brain delivery

Antibody-drug conjugates for targeted CNS delivery

FcRn antagonists for accelerated antibody clearance

Key Challenges

Clinical Trial Failures

Gantenerumab (Roche) - Phase III failed to meet endpoints
Crenezumab (Roche) - Phase III failed in preclinical AD
Solanezumab (Eli Lilly) - Multiple Phase III failures
Semorinemab (Roche) - Phase II failed primary endpoint

Risk Factors

ARIA (Amyloid-Related Imaging Abnormalities) - Brain edema risk
High development costs - $1-2B per successful program
Long trial durations - 18-24 months for cognitive endpoints
Patient recruitment - Early-stage patients difficult to identify

Cross-Links

[Novel Therapy Index](/ideas/novel-therapy-index)
[Alzheimer's Disease Treatment](/therapeutics/alzheimers-disease-treatment)
[Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment)
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
[Tau Pathology](/mechanisms/tau-pathology)
[Alpha-Synuclein Pathophysiology](/mechanisms/alpha-synuclein-pathophysiology)

References

[Mintun MA et al, Donanemab in Early Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36449459/)

[Ostrowitzki S et al, Gantenerumab for Alzheimer's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/36449458/)

[van Dyck CH et al, Lecanemab in Early Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36449457/)

📖 View canonical wiki page →

Related Entities

investment-antibody-therapeutics-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	investment-antibody-therapeutics-neurodegeneration
kg_node_id	None
entity_type	investment
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c80e875aa5fc
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'investment-antibody-therapeutics-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

546

Outgoing

705

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Antibody Therapeutics Investment Landscape for Neurodegeneration

Overview

Overview

Market Landscape

Key Players

Investment Themes

Clinical Pipeline

Anti-Amyloid Antibodies

Anti-Tau Antibodies

Anti-Alpha-Synuclein Antibodies

Bispecific Antibodies

Funding Trends

Investment by Indication (2024-2026)

Recent Financing Rounds

Gap Analysis

Unmet Needs

Investment Opportunities

Key Challenges

Clinical Trial Failures

Risk Factors

Cross-Links

See Also

References

💬 Discussion